News

Deal Announcements

APT Pharmaceuticals Nets Series B Venture Capital

Wednesday, October 1, 2008 5:44:00 AM PDT | VentureDeal Staff
Burlingame, California  --  Pharmaceutical company APT Pharmaceuticals announced that it has raised $32 million in its second round of institutional venture capital financing.

APT is developing treatments for chronic pulmonary obstructive disease (COPD), rhinitis, asthma and rhinovirus.

Three Arch Partners led the round, which included InterWest Partners, Pinnacle Ventures, Charter Life Sciences Fund, Great Point Partners, Versant Ventures and Vivo Ventures.

The company said it would use the proceeds to complete its Pphase III program for cyclosporine inhalation solution.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1